Department of Neurology, Universidade Federal de Sao Paulo, São Paulo, Brazil.
Department of Pediatrics, Universidade de São Paulo, São Paulo, Brazil.
Brain Behav. 2020 Apr;10(4):e01590. doi: 10.1002/brb3.1590. Epub 2020 Mar 11.
Chronic pain and fatigue are the main symptoms of postpoliomyelitis syndrome (PPS). This study aimed to evaluate the efficacy and safety of an anthroposophic multimodal treatment for chronic pain in PPS outpatients.
A twelve-week, four-arm, randomized, double-blind, placebo-controlled, phase 2 prospective clinical trial was designed to compare four groups (n = 48): groups A and B received daily active experimental transdermal gel (ETG) or placebo gel (PTG), respectively; groups C and D received weekly external therapies, art therapies, and neurofunctional reorganization, plus either daily ETG or PTG, respectively. The pain symptoms were evaluated through a visual analogue scale (VAS), the McGill questionnaire, and thermography. Quality of life and resilience were evaluated by the WHOQOL-BREF and Antonovsky sense of coherence questionnaires applied at baseline and after the interventions.
No related adverse events occurred, and 10% of the patients reports dysphagia improvement. In the groups C and D, pain reduction was statistically significant in both the placebo group (p = .02, d = 1.315) and in the ETG (p = .005, d = 2.035). However, following the week-to-week evolution of pain with the concomitant use of the ETG, this significant pain reduction occurred earlier from the 4th week and continued to decrease (p = .016, d = 1.369). In the group that received the complete multimodal treatment, the greatest significant benefit in increasing quality of life occurred in the physical domain and elevation in resilience with an emphasis on meaning and comprehension domains.
The anthroposophic multimodal treatment group presented both safety and efficacy as an analgesic in the groups that received the nonpharmacological therapies, much earlier when associated with the ETG. The multimodal approach corresponded to the pattern of better efficacy for both pain reduction and improvement in quality of life and resilience.
慢性疼痛和疲劳是脊髓灰质炎后综合征(PPS)的主要症状。本研究旨在评估顺势疗法多模式治疗对门诊慢性疼痛的疗效和安全性。
设计了一项为期 12 周、四臂、随机、双盲、安慰剂对照、2 期前瞻性临床试验,比较了四组(n=48):A 组和 B 组分别接受每日活性实验透皮凝胶(ETG)或安慰剂凝胶(PTG);C 组和 D 组分别接受每周的外部治疗、艺术治疗和神经功能重组,同时接受每日 ETG 或 PTG。通过视觉模拟评分(VAS)、麦吉尔问卷和热成像评估疼痛症状。采用 WHOQOL-BREF 和 Antonovsky 意义感问卷评估生活质量和适应力,在基线和干预后进行评估。
无相关不良事件发生,10%的患者报告吞咽困难改善。在 C 组和 D 组中,安慰剂组(p=0.02,d=1.315)和 ETG 组(p=0.005,d=2.035)的疼痛均有统计学意义的减轻。然而,随着 ETG 的使用,疼痛每周的变化表明,从第 4 周开始,疼痛明显减轻,并持续下降(p=0.016,d=1.369)。在接受完整多模式治疗的组中,生活质量在身体领域显著增加,适应力显著提高,重点是意义和理解领域。
在接受非药物治疗的组中,顺势疗法多模式治疗既安全又有效,与 ETG 联合使用时,效果更早出现。多模式方法与更好的疗效模式相对应,既减轻了疼痛,又提高了生活质量和适应力。